PL2206727T3 - Przeciwciało skierowane na białko Siglec-15 związane z osteoklastami - Google Patents

Przeciwciało skierowane na białko Siglec-15 związane z osteoklastami

Info

Publication number
PL2206727T3
PL2206727T3 PL08838427T PL08838427T PL2206727T3 PL 2206727 T3 PL2206727 T3 PL 2206727T3 PL 08838427 T PL08838427 T PL 08838427T PL 08838427 T PL08838427 T PL 08838427T PL 2206727 T3 PL2206727 T3 PL 2206727T3
Authority
PL
Poland
Prior art keywords
related protein
antibody targeting
protein siglec
targeting osteoclast
osteoclast
Prior art date
Application number
PL08838427T
Other languages
English (en)
Inventor
Yoshiharu Hiruma
Eisuke Tsuda
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40549216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2206727(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of PL2206727T3 publication Critical patent/PL2206727T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
PL08838427T 2007-10-11 2008-10-08 Przeciwciało skierowane na białko Siglec-15 związane z osteoklastami PL2206727T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007265420 2007-10-11
EP08838427.6A EP2206727B1 (en) 2007-10-11 2008-10-08 ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
PCT/JP2008/068287 WO2009048072A1 (ja) 2007-10-11 2008-10-08 破骨細胞関連蛋白質Ｓｉｇｌｅｃ－１５を標的とした抗体

Publications (1)

Publication Number Publication Date
PL2206727T3 true PL2206727T3 (pl) 2015-08-31

Family

ID=40549216

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08838427T PL2206727T3 (pl) 2007-10-11 2008-10-08 Przeciwciało skierowane na białko Siglec-15 związane z osteoklastami

Country Status (24)

Country Link
US (5) US8546540B2 (pl)
EP (2) EP2206727B1 (pl)
JP (4) JPWO2009048072A1 (pl)
KR (2) KR101577935B1 (pl)
CN (2) CN108130327A (pl)
AU (2) AU2008311698C1 (pl)
BR (1) BRPI0818437B8 (pl)
CA (2) CA2875310A1 (pl)
CY (1) CY1116432T1 (pl)
DK (1) DK2206727T3 (pl)
ES (2) ES2677246T3 (pl)
HR (1) HRP20150485T1 (pl)
HU (1) HUE025262T2 (pl)
IL (2) IL204607A (pl)
MX (1) MX2010003884A (pl)
NZ (1) NZ583397A (pl)
PL (1) PL2206727T3 (pl)
PT (1) PT2206727E (pl)
RU (2) RU2475499C2 (pl)
SG (2) SG10201605897RA (pl)
SI (1) SI2206727T1 (pl)
TW (1) TWI511740B (pl)
WO (1) WO2009048072A1 (pl)
ZA (1) ZA201001339B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
PL2206727T3 (pl) * 2007-10-11 2015-08-31 Daiichi Sankyo Co Ltd Przeciwciało skierowane na białko Siglec-15 związane z osteoklastami
KR101690340B1 (ko) 2009-04-09 2016-12-27 다이이찌 산쿄 가부시키가이샤 항 Ｓｉｇｌｅｃ-15 항체
KR20130066682A (ko) * 2010-10-05 2013-06-20 다이이찌 산쿄 가부시키가이샤 항체 표적 파골세포－관련 단백질 ｓｉｇｌｅｃ－１５
US20130280260A1 (en) * 2010-10-13 2013-10-24 Tokyo Women's Medical University Osteoclastogenesis inhibitor containing anti-vdac antibody
EP2753356B1 (en) 2011-09-09 2021-12-22 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
US9464133B2 (en) * 2012-03-30 2016-10-11 Daiichi Sankyo Company, Limited CDR-modified anti-Siglec-15 antibody
CA2868965A1 (en) * 2012-03-30 2013-10-03 Daiichi Sankyo Company, Limited Anti-siglec-15 antibody
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
US9951123B2 (en) 2013-09-30 2018-04-24 Daiichi Sankyo Company, Limited Anti-LPS O11 antibody
US10479832B2 (en) 2014-03-31 2019-11-19 Universiteit Gent Method of treating bone disease
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
BR112018009361A8 (pt) * 2015-11-10 2019-02-26 Univ Yale composições e métodos para o tratamento de doenças autoimunes e de câncer
EP4360714A3 (en) * 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
ES2982558T3 (es) 2016-09-21 2024-10-16 Nextcure Inc Anticuerpos para Siglec-15 y métodos de uso de los mismos
WO2018147245A1 (ja) 2017-02-07 2018-08-16 第一三共株式会社 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
CN110913905A (zh) 2017-06-30 2020-03-24 国立大学法人北海道大学 不产生生长障碍的小儿骨质疏松症治疗药
SG11202000759XA (en) 2017-07-27 2020-02-27 Daiichi Sankyo Co Ltd Anti-cd147 antibody
BR112020021266A2 (pt) 2018-05-31 2021-01-26 Daiichi Sankyo Company, Limited anticorpo anti-tlr7 humano
EP3831853A4 (en) 2018-07-27 2022-06-01 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
WO2020036869A1 (en) 2018-08-16 2020-02-20 Emd Millipore Corporation Closed bioprocessing device
CN111378043B (zh) * 2020-02-19 2021-02-09 南京医科大学 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用
CN112159475B (zh) * 2020-10-10 2021-04-30 南京凯地生物科技有限公司 Siglec-15单克隆抗体及其应用
CN112625132B (zh) * 2021-01-15 2022-08-02 沈阳荣欣生物制药科技有限公司 纳米抗体及其编码基因、表达载体、宿主细胞和应用
CN114957468A (zh) * 2021-02-25 2022-08-30 石药集团巨石生物制药有限公司 一种抗Siglec15抗体及其用途
CN112979761B (zh) * 2021-03-19 2021-12-10 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN112961214B (zh) * 2021-03-19 2022-08-02 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN113577283A (zh) * 2021-07-19 2021-11-02 河北医科大学第三医院 Siglec-15抑制剂在制备防治骨巨细胞瘤药物中的应用
CN114807052A (zh) * 2022-06-07 2022-07-29 江苏亲科生物研究中心有限公司 Siglec15单克隆抗体及其制备方法和用途
WO2024022008A1 (zh) * 2022-07-26 2024-02-01 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EP2336168A1 (en) 1997-04-15 2011-06-22 Sankyo Company Limited Novel protein and method for producing the protein
WO1999058515A1 (en) 1998-05-08 1999-11-18 Toyama Chemical Co., Ltd. Novel spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and ap-1 inhibitors containing the same
JP2004516012A (ja) * 2000-07-21 2004-06-03 ブリストル−マイヤーズ スクイブ カンパニー 新規シグレック類およびそれらの用途
CA2428140A1 (en) 2000-11-08 2002-05-16 Incyte Genomics, Inc. Secreted proteins
US7608704B2 (en) * 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
EP1369479A4 (en) * 2001-02-15 2004-12-08 Mochida Pharm Co Ltd Novel cell adhesion molecule specific to activated leukocyte
MY143582A (en) * 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
WO2003048305A2 (en) * 2001-11-13 2003-06-12 Incyte Genomics, Inc. Receptors and membrane-associated proteins
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
PL375041A1 (pl) * 2002-04-05 2005-11-14 Amgen Inc. Ludzkie neutralizujące przeciwciała anty-OPGL, będące selektywnymi inhibitorami ścieżki OPGL
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
JP4633491B2 (ja) * 2004-02-12 2011-02-16 第一三共株式会社 破骨細胞関連タンパク質を標的とした抗体
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US7405037B2 (en) 2004-05-07 2008-07-29 Lonza Walkersville, Inc. Methods and tools for detecting collagen degradation
CN101035807A (zh) * 2004-06-09 2007-09-12 泰勒公司 Siglec－6相关疾病的诊断和治疗
JP4604184B2 (ja) * 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
GB0521991D0 (en) * 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
PL2206727T3 (pl) * 2007-10-11 2015-08-31 Daiichi Sankyo Co Ltd Przeciwciało skierowane na białko Siglec-15 związane z osteoklastami
KR101690340B1 (ko) 2009-04-09 2016-12-27 다이이찌 산쿄 가부시키가이샤 항 Ｓｉｇｌｅｃ-15 항체
ES2533028T3 (es) 2010-06-23 2015-04-07 Creissels Technologies Instalación de cables aéreos y de un vehículo con servocontrol, sin brazo de suspensión
KR20130066682A (ko) 2010-10-05 2013-06-20 다이이찌 산쿄 가부시키가이샤 항체 표적 파골세포－관련 단백질 ｓｉｇｌｅｃ－１５
US9464133B2 (en) 2012-03-30 2016-10-11 Daiichi Sankyo Company, Limited CDR-modified anti-Siglec-15 antibody
CA2868965A1 (en) 2012-03-30 2013-10-03 Daiichi Sankyo Company, Limited Anti-siglec-15 antibody

Also Published As

Publication number Publication date
SG10201605897RA (en) 2016-09-29
US10723800B2 (en) 2020-07-28
JP2016074694A (ja) 2016-05-12
EP2206727A1 (en) 2010-07-14
US9090692B2 (en) 2015-07-28
IL204607A0 (en) 2010-11-30
RU2010106639A (ru) 2011-08-27
HK1145847A1 (en) 2011-05-06
US10308715B2 (en) 2019-06-04
US20150344578A1 (en) 2015-12-03
CN108130327A (zh) 2018-06-08
HK1209135A1 (en) 2016-03-24
ES2677246T3 (es) 2018-07-31
BRPI0818437A2 (pt) 2015-05-12
IL204607A (en) 2016-03-31
CA2698326A1 (en) 2009-04-16
RU2012132678A (ru) 2014-02-10
KR20100065153A (ko) 2010-06-15
JP6116652B2 (ja) 2017-04-19
JP6440759B2 (ja) 2018-12-19
MX2010003884A (es) 2010-04-30
AU2008311698C1 (en) 2014-03-06
AU2012201263A1 (en) 2012-03-22
KR101577935B1 (ko) 2015-12-16
JP2017155044A (ja) 2017-09-07
IL234078A0 (en) 2014-09-30
US20180037656A1 (en) 2018-02-08
BRPI0818437B1 (pt) 2021-03-30
AU2012201263B9 (en) 2017-06-01
US20100209428A1 (en) 2010-08-19
PT2206727E (pt) 2015-08-05
US9815899B2 (en) 2017-11-14
WO2009048072A1 (ja) 2009-04-16
HUE025262T2 (en) 2016-02-29
AU2008311698A1 (en) 2009-04-16
US8546540B2 (en) 2013-10-01
EP2206727A4 (en) 2011-03-02
US20120251485A1 (en) 2012-10-04
ES2540733T3 (es) 2015-07-13
HRP20150485T1 (xx) 2015-06-19
EP2907826B1 (en) 2018-05-30
CN101896501B (zh) 2017-11-07
CY1116432T1 (el) 2017-02-08
JP5845207B2 (ja) 2016-01-20
US20120230988A1 (en) 2012-09-13
SG187523A1 (en) 2013-02-28
IL234078B (en) 2018-08-30
KR20150031489A (ko) 2015-03-24
SI2206727T1 (sl) 2015-06-30
RU2475499C2 (ru) 2013-02-20
KR101534884B1 (ko) 2015-07-08
AU2012201263B2 (en) 2017-04-20
CN101896501A (zh) 2010-11-24
TWI511740B (zh) 2015-12-11
BRPI0818437A8 (pt) 2019-01-15
JPWO2009048072A1 (ja) 2011-02-17
JP2013144708A (ja) 2013-07-25
CA2698326C (en) 2015-03-17
EP2907826A1 (en) 2015-08-19
BRPI0818437B8 (pt) 2021-05-25
ZA201001339B (en) 2010-10-27
CA2875310A1 (en) 2009-04-16
NZ583397A (en) 2012-03-30
AU2008311698B2 (en) 2011-12-01
TW200927168A (en) 2009-07-01
DK2206727T3 (en) 2015-07-06
EP2206727B1 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
ZA201001339B (en) Antibody targeting osteoclast-related protein Siglec-15
HUS2100038I1 (hu) Anti-CD20 antitest készítmények
PL3118220T3 (pl) Białko
IL204537A0 (en) Modified antibody constant region
ZA200906699B (en) Insecticidal proteins
GB0708002D0 (en) Antibodies
SI2126093T1 (sl) Izboljšanje priprave proteinov
ZA201003131B (en) Anti-rsv g protein antibodies
SI2200700T1 (sl) Nova protitelesa
PL2146745T3 (pl) Pięcioswoiste przeciwciało
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
BRPI0814971A2 (pt) Proteína
GB0718737D0 (en) Antibodies
IL205073A0 (en) Anti-bst2 antibody
IL236236A (en) Antibodies to the fam26f polypeptide
GB0702888D0 (en) Novel Antibodies
GB0815788D0 (en) Therapeutic antibodies
GB0719231D0 (en) Protein
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
GB0720563D0 (en) Protein
GB0700759D0 (en) Novel fusion protein
GB0704526D0 (en) Pathogenic protein
IL206541A0 (en) Novel protein
GB0713302D0 (en) Protein
GB0719236D0 (en) Protein